CLINICAL TRIAL

Treatment for Tachycardia

Waitlist Available · 18+ · All Sexes · Bronx, NY

This study is evaluating whether a new surgical procedure is better than standard treatment for ventricular tachycardia.

See full description

About the trial for Tachycardia

Eligible Conditions
Tachycardia · Ventricular Tachycardia (VT) · Cardiomyopathies · Tachycardia, Ventricular

Treatment Groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.

Control Group 1
Endocardial- Epicardial ablation
PROCEDURE
+
Endocardial ablation
PROCEDURE
Control Group 2
Antiarrhythmic medications
DRUG
+
Endocardial- Epicardial ablation
PROCEDURE
+
Endocardial ablation
PROCEDURE

Eligibility

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Patient with ≥ 1 episode of VT (i.e., Sustained VT more than 30 seconds or VT with any ICD therapy)
Patients with ischemic cardiomyopathy, EF less than 50%, documented history of CAD
Male or female, aged 18 or greater
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 24 and 60 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 and 60 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 24 and 60 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 2 primary outcomes and 5 secondary outcomes in patients with Tachycardia. Measurement will happen over the course of Up to 4 hours (During ablation procedure).

Procedure duration and fluoroscopy time
UP TO 4 HOURS (DURING ABLATION PROCEDURE)
Procedure duration and fluoroscopy time
UP TO 4 HOURS (DURING ABLATION PROCEDURE)
Freedom from documented VT episodes after second intervention
12 MONTHS AFTER SECOND INTERVENTION
Freedom from documented VT episodes (greater than 30 seconds) at 12 months after the second ablation procedure or on two antiarrhythmics combined.
12 MONTHS AFTER SECOND INTERVENTION
Cost-effectiveness analysis
12 MONTHS
The CEA will examine the cost of health care resources and health outcomes from the ablation procedure to 1-year postoperatively. The costs will include all health care utilization during this time. Health care utilization, and associated costs, related to the patients' condition, the procedure and adverse events will be the basis of a sensitivity analysis.
12 MONTHS
Freedom from documented VT episodes
12 MONTHS
Freedom from documented VT episodes (greater than 30 seconds) at 12 months after the first ablation procedure or on antiarrhythmic medication.
12 MONTHS
Incidence of peri-procedural and 12-month post procedural complications
12 MONTHS
These complications include but not limited to ischemic stroke, cardiac perforation, rehospitalization, and death.
12 MONTHS
Number of repeat procedures
12, 24 MONTHS
Number of repeat ablations
12, 24 MONTHS
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of tachycardia?

For all patients with heartburn, tachycardia is not a cause of heartburn-like symptoms. Tachycardia is often not identified due to a lack of testing or the patient's poor language skills, so the diagnosis needs to be made based on symptoms and an electrocardiogram. For patients with tachycardia, the most dangerous is atrial fibrillation, which can lead to stroke or death.

Anonymous Patient Answer

What are common treatments for tachycardia?

In the US, one-third of all outpatients treated for [congestive heart failure](https://www.withpower.com/clinical-trials/congestive-heart-failure) use β-blockers. Tachycardia secondary to heart failure may be treated with beta blockers, ACE inhibitors, calcium channel blockers, amiodarone, or digoxin. Beta-blockers are preferred over others and may not be necessary in all patients. Patients who do not adequately respond to one of these treatments should be referred for further evaluation.

Anonymous Patient Answer

Can tachycardia be cured?

Tachycardia is frequently associated with a significant decrease in ventricular rate and an improvement in heart failure symptoms over 6, 12, and 18 months of medication.

Anonymous Patient Answer

How many people get tachycardia a year in the United States?

Around 60 million tachycardia admissions occur in the United States each year. As many as 1 in 5 patients admitted to the emergency department are admitted on account of tachycardia. There is an apparent difference in the age of presentation, with around two-thirds of admissions occurring in patients over 65 years of age, compared with around 15% of admissions in the under 55 age group. A more serious form of tachycardia than supraventricular tachycardia occurs in over 20% of tachycardia admissions.

Anonymous Patient Answer

What is tachycardia?

Tachycardia is a rate that is more than what is normal (usually between 80 and 120 beats per minute). It has been described as being either supraventricular or ventricular. In newborn babies, the rate is between 80 and 100 beats per minute.\n

Anonymous Patient Answer

What causes tachycardia?

A variety of underlying conditions can cause tachycardia, including autonomic dysregulation, hypoxia, hyperthyroidism, and metabolic acidosis. Cardiac pathology may cause tachycardia by a variety of mechanisms, including increased cardiac output from the pumping action of the heart, increased cardiac vagal tone, or abnormal heart rate responses to the sympathetic nervous system. Treatment of tachycardia is aimed toward the underlying cause; antiarrhythmia drugs, such as digitalis therapy and beta blockers, and medications with antihyperthyroid effects, such as propylthiouracil, can be useful as adjuncts to appropriate therapy of the underlying root cause.

Anonymous Patient Answer

How serious can tachycardia be?

Exercise-associated tachycardia can have several serious underlying causes. In addition to evaluating for cardiac disease, a patient's history is vital. Symptoms and history must be evaluated to determine the underlying cause.

Anonymous Patient Answer

What is the average age someone gets tachycardia?

Older people with tachycardia have many risk factors for complications such as congestive heart failure, pulmonary diseases, and cerebrovascular Disease, and they are in danger of developing these complications over time as heart rate continues to increase. In order to prevent the complications associated with tachycardia, we need to modify lifestyle risk factors in older people like diet, smoking, etc. and to control blood pressure and other related diseases in older people like hypertension and diabetes.

Anonymous Patient Answer

What does treatment usually treat?

In general, patients with SS use many medications for various medical conditions. More study is necessary to determine if these medications are effective in reducing symptoms.

Anonymous Patient Answer

Has treatment proven to be more effective than a placebo?

Although there is a trend toward better improvement with the sham therapy than with placebo therapy, the data do not have sufficient data to identify an effective treatment. The study design did not include a control group.

Anonymous Patient Answer

Is treatment typically used in combination with any other treatments?

Treatment in combination is typically used in patients with other medical conditions. In many patients with tachyarrhythmia, antiarrhythmic treatments or antianginal therapy may be accompanied by treatment of symptoms of hypotension, hyperinsulinemia or hypoglycemia or the medication may be used to control electrolyte abnormalities or metabolic conditions. In addition, most patients with tachyarrhythmia will have multiple concurrent chronic conditions. Therefore therapy used in combination with treatment of the other concurrent diseases may have a significant effect on the rate of tachyarrhythmia control. To find treatment for tachyarrhythmia in combination with other conditions, use [Power(http://www.withpower.

Anonymous Patient Answer

What is the primary cause of tachycardia?

The data suggest that there are many causes involved in tachycardia which needs to be explored for each patient who presents to the emergency department. However, we recommend that the most important considerations are the patient's history and physical examination.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Tachycardia by sharing your contact details with the study coordinator.